Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s

Navigating neuroimaging in Alzheimer disease care

PET imaging is playing an increasingly critical role in managing AD, but how can you effectively integrate it into clinical practice? Our expert-led program will empower you with practical strategies and real-world case studies.

This content is intended for healthcare professionals outside of the UK.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in:

11-04-2025 | Type 2 Diabetes | Practical Issues and Updates

Treat metabolic diseases with effective and approved therapies while new treatments are under investigation

Author: Aisling McGuigan

Published in: Drugs & Therapy Perspectives | Issue 4/2025

Login to get access

Abstract

Management of metabolic diseases, such as obesity and type 2 diabetes, typically requires pharmacotherapeutics in addition to lifestyle changes. Several glucagon-like peptide-1 receptor (GLP-1R) agonists have acquired US FDA approval for treatment of these diseases, based on efficacy in glycaemic control and weight management in randomised controlled trials (RCTs). Recently, poly-agonist drugs that target GLP-1R and other metabolic signalling pathways, such as glucose-dependent insulinotropic receptors and glucagon receptors, have shown superior glycaemic control and weight loss effects compared with mono-agonist drugs in RCTs. This highlights the potential benefit of activating multiple gut hormone signalling pathways to achieve improved outcomes in the pharmacological treatment of metabolic diseases.
Literature
1.
Chew NWS, Ng CH, Tan DJH, et al. The global burden of metabolic disease: data from 2000 to 2019. Cell Metab. 2023;35(3):414-28.e3.PubMedCrossRef
2.
American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S145–57.CrossRef
3.
American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158–78.CrossRef
4.
Allard C, Cota D, Quarta C. Poly-agonist pharmacotherapies for metabolic diseases: hopes and new challenges. Drugs. 2024;84(2):127–48.PubMedCrossRef
5.
6.
Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291–301.PubMedPubMedCentralCrossRef
7.
Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–54.PubMedCrossRef
8.
Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):241–60.CrossRef
9.
Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label randomized, clinical trial. Diabetes Care. 2018;41(2):258–66.PubMedCrossRef
10.
Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–66.PubMedCrossRef
11.
Kaku K, Yamada Y, Watada H, et al. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial. Diabetes Obes Metab. 2018;20(5):1202–12.PubMedPubMedCentralCrossRef
12.
Seino Y, Terauchi Y, Osonoi T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):378–88.PubMedCrossRef
13.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.PubMedCrossRef
14.
Bergmann NC, Davies MJ, Lingvay I, et al. Semaglutide for the treatment of overweight and obesity: a review. Diabetes Obes Metab. 2023;25(1):18–35.PubMedCrossRef
15.
Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2015;39:1443–51.CrossRef
16.
17.
Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–86.PubMedCrossRef
18.
Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834–44.PubMedCrossRef
19.
Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–9.PubMedCrossRef
20.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.PubMedCrossRef
21.
Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–25.PubMedCrossRef
22.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–84.PubMedCrossRef
23.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32.PubMedCrossRef
24.
Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–51.PubMedPubMedCentralCrossRef
25.
Rodbard HW, Dougherty T, Taddei-Allen P. Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care. Am J Manag Care. 2020;26(16 Suppl):S335–43.PubMed
26.
27.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.PubMedCrossRef
28.
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.PubMedCrossRef
29.
Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811–24.PubMedCrossRef
30.
Ludvik B, Giorgino F, Jodar E, et al. Efficacy and safety of tirzepatide, a dual GIP/GLP-1 receptor agonist, compared with insulin degludec in patients with type 2 diabetes (SURPASS-3) [abstract no. 78-LB]. Diabetes. 2021;70(Suppl 1):78.CrossRef
31.
Ussher JR, Baggio LL, Campbell JE, et al. Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metab. 2014;3(5):507–17.PubMedPubMedCentralCrossRef
32.
McLean BA, Wong CK, Kabir MG, et al. Glucagon-like peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction. Mol Metab. 2022;66:101641.PubMedPubMedCentralCrossRef
33.
Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336–47.PubMedCrossRef
34.
Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384–90.PubMedCrossRef
35.
Faillie JL, Yu OH, Yin H, et al. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176(10):1474–81.PubMedCrossRef
36.
Butler PC, Elashoff M, Elashoff R, et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care. 2013;36(7):2118–25.PubMedPubMedCentralCrossRef
37.
Chen W, Cai P, Zou W, et al. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database. Front Endocrinol (Lausanne). 2024;15:1330936.PubMedPubMedCentralCrossRef
38.
Sikirica MV, Martin AA, Wood R, et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403–12.PubMedPubMedCentralCrossRef
39.
Hædersdal S, Andersen A, Knop FK, et al. Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases. Nat Rev Endocrinol. 2023;19:321–35.PubMedCrossRef
40.
Friedrichsen MH, Endahl L, Kreiner FF, et al. Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity. Mol Metab. 2023;78:101801.PubMedPubMedCentralCrossRef
41.
Nahra R, Wang T, Gadde KM, et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care. 2021;44(6):1433–42.PubMedPubMedCentralCrossRef
42.
Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023;14(1):8289.PubMedPubMedCentralCrossRef
43.
Jiang H, Ji L, Zhang Y, et al. A phase 2 study of mazdutide 9 mg in Chinese adults with BMI of 30 kg/m2 or more [abstract no. 1866-LB]. Diabetes. 2024;73(Suppl 1):1866.CrossRef
44.
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity—a phase 2 trial. N Engl J Med. 2023;389(6):514–26.PubMedCrossRef
45.
Abdelmalek M, Choi J, Kim Y, et al. HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: a phase 1b/2a, multicenter, randomized, placebo-controlled trial [abstract no. LBP03]. J Hepatol. 2020;73:S124.CrossRef
46.
47.
Veniant MM, Lu SC, Atangan L, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024;6(2):290–303.PubMedPubMedCentralCrossRef
Metadata
Title
Treat metabolic diseases with effective and approved therapies while new treatments are under investigation
Author
Aisling McGuigan
Publication date
11-04-2025
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 4/2025
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-025-01154-4

Other articles of this Issue 4/2025

Take a personalised approach when treating older adults with rosacea

Dose rounding: a cost-savings fix or the new standard?

Manage chronic hand eczema with conventional treatments, but emerging therapies show promise

Effective drug dosage rounding reduces healthcare expenses in the Japanese healthcare system

Consider topical superpotent corticosteroids for oral lichen planus; reserve systemic therapy for severe disease

Iptacopan in paroxysmal nocturnal haemoglobinuria: a profile of its use